The SARM1 targeting therapeutics market is projected to grow at a CAGR of 102.1%
SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share